Serum Proprotein Convertase Subtilisin/ Kexin Type 9 Levels are Increased in Patients with Transient Ischemic Attack Thomas Tzimas, Eleni Pappa, Sebastien Filippas-Ntekouan, Maria Georgoula, Angelos Liontos, Constantinos Tellis, Alexandros D. Tselepis, Haralampos Milionis
PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting – A 2-year regional lipid clinic experience Georgia Anastasiou, George Liamis, Haralampos Milionis, Moses Elisaf, Eliza Christopoulou, Theodora Dimitriou, Evangelos N. Liberopoulos
Competing risks’ analysis in cardiovascular disease epidemiology; – Τhe case of ATTICA study (2002-2012) Thomas Tsiampalis, Demosthenes Panagiotakos
Diagnostic methods and pharmacological management of non-alcoholic fatty liver disease – There is still room for improvement Chrysoula Boutari, Panagiotis Pappas, Konstantinos Tziomalos, Vasileios Athyros, Asterios Karagiannis